The importance of being open and transparent
It is crucially important for Amgen to collaborate in the process of discovering, developing, improving and making available innovative therapies that help patients. Our partners in this are care providers, care institutions and patient organizations. We understand the societal importance of us being open and transparent about these collaborations and any corresponding compensation. We report annually on the financial links between Amgen and professionals, institutions and other parties involved in care. With the approval of the collaborating partner, these are published in the Healthcare Transparency Register.
We are transparent when it comes to our research and development (R&D) costs. Details are published on the website of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
These cover R&D expenditure on clinical trials and trials outside of the clinical environment, inclusive of all related costs. The first reporting period is the 2015 calendar year.
2020 R&D Transfer of value rapport Nederland (Update 27/05/2021)
2019 R&D Transfer of value rapport Nederland (Update 2/06/2020)
2018 R&D Transfer of value rapport Nederland (Update 24/05/2019)
EFPIA Disclosure Code Methodological Note (English)
Amgen EFPIA Disclosure Code Self-Certification Scheme